Dr. Manel Juan, expert in immunology, visits the Josep Carreras Leukaemia Research Institute
"There are many challenges. Obviously the main one is to expand the success of CART19 to other CARTs, especially for lymphomas. It is also important to control their side effects and, as in all complicated and expensive therapies, another important challenge is to find a way of making them available to everyone who needs them without that availability depending on the financial resources or location of the people concerned."
Today we have the great pleasure of welcoming Dr. Manel Juan, head of Clinical Immunology of the Barcelona Hospital Clínic Immunology Service, to the Catalan Institute for Oncology/Germans Trias i Pujol Campus of the Josep Carreras Leukaemia Research Institute (IJC).
Dr. Juan has led a symposium at our centre entitled, "Our experience of a CART19 approach in Barcelona, or CARs for anti-tumour immunotherapy".
Dr. Manel Juan qualified as a doctor from the University of Barcelona, he is a specialist in immunotherapy and is also qualified in medicine and surgery (Barcelona University). He sits on the Council of the Grupo Español de Terapias Inmunológicas en Cáncer (Spanish immunological therapy for cancer group). He is the president of the Comisión Nacional de la Especialidad de Inmunología (Spanish immunology committee). + info here
When he is not working Dr. Juan likes, above all, to spend time with his family (not enough time and for a long time), to be with friends, go to the cinema and travel.
Today we want to ask him a little more about the current challenges facing immunology.